Kiniksa Pharmaceuticals International, plc Share-based Payment Arrangement, Expense in USD from Q2 2017 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Kiniksa Pharmaceuticals International, plc quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q2 2017 to Q3 2025.
  • Kiniksa Pharmaceuticals International, plc Share-based Payment Arrangement, Expense for the quarter ending September 30, 2025 was $10.1M, a 29.6% increase year-over-year.
  • Kiniksa Pharmaceuticals International, plc Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2025 was $35.1M, a 16.2% increase year-over-year.
  • Kiniksa Pharmaceuticals International, plc annual Share-based Payment Arrangement, Expense for 2024 was $30.7M, a 13.1% increase from 2023.
  • Kiniksa Pharmaceuticals International, plc annual Share-based Payment Arrangement, Expense for 2023 was $27.1M, a 8.08% increase from 2022.
  • Kiniksa Pharmaceuticals International, plc annual Share-based Payment Arrangement, Expense for 2022 was $25.1M, a 0.21% decline from 2021.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Growth (%)

Kiniksa Pharmaceuticals International, plc Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 $35.1M $10.1M +$2.32M +29.6% Jul 1, 2025 Sep 30, 2025 10-Q 2025-10-28
Q2 2025 $32.7M $8.88M +$1.51M +20.5% Apr 1, 2025 Jun 30, 2025 10-Q 2025-07-29
Q1 2025 $31.2M $7.75M +$542K +7.52% Jan 1, 2025 Mar 31, 2025 10-Q 2025-04-29
Q4 2024 $30.7M $8.3M +$525K +6.75% Oct 1, 2024 Dec 31, 2024 10-K 2025-02-25
Q3 2024 $30.2M $7.83M +$1.04M +15.3% Jul 1, 2024 Sep 30, 2024 10-Q 2025-10-28
Q2 2024 $29.1M $7.36M +$890K +13.7% Apr 1, 2024 Jun 30, 2024 10-Q 2025-07-29
Q1 2024 $28.2M $7.21M +$1.09M +17.8% Jan 1, 2024 Mar 31, 2024 10-Q 2025-04-29
Q4 2023 $27.1M $7.77M +$1.4M +22% Oct 1, 2023 Dec 31, 2023 10-K 2025-02-25
Q3 2023 $25.7M $6.79M +$747K +12.4% Jul 1, 2023 Sep 30, 2023 10-Q 2024-10-29
Q2 2023 $25M $6.47M -$203K -3.04% Apr 1, 2023 Jun 30, 2023 10-Q 2024-07-25
Q1 2023 $25.2M $6.12M +$84K +1.39% Jan 1, 2023 Mar 31, 2023 10-Q 2024-04-25
Q4 2022 $25.1M $6.37M +$241K +3.93% Oct 1, 2022 Dec 31, 2022 10-K 2025-02-25
Q3 2022 $24.9M $6.04M -$158K -2.55% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-02
Q2 2022 $25M $6.68M +$959K +16.8% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-01
Q1 2022 $24.1M $6.03M -$1.1M -15.4% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-04
Q4 2021 $25.2M $6.13M -$126K -2.01% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-28
Q3 2021 $25.3M $6.2M +$641K +11.5% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 $24.7M $5.72M +$866K +17.9% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 $23.8M $7.13M +$2.92M +69.3% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-05
Q4 2020 $20.9M $6.26M +$1.29M +26% Oct 1, 2020 Dec 31, 2020 10-K 2023-03-02
Q3 2020 $19.6M $5.56M +$1.8M +47.9% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 $17.8M $4.85M +$1.39M +40% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-05
Q1 2020 $16.4M $4.21M +$1.32M +45.5% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q4 2019 $15.1M $4.97M +$2.38M +92.3% Oct 1, 2019 Dec 31, 2019 10-K 2022-02-24
Q3 2019 $12.7M $3.76M +$2.26M +150% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 $10.4M $3.46M +$2.41M +227% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-04
Q1 2019 $8.04M $2.89M +$2.34M +418% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-04
Q4 2018 $5.7M $2.58M Oct 1, 2018 Dec 31, 2018 10-K 2021-02-25
Q3 2018 $1.5M +$1.18M +366% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-05
Q2 2018 $1.06M +$945K +829% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-13
Q1 2018 $558K Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-07
Q3 2017 $322K Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-06
Q2 2017 $114K Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-06

Kiniksa Pharmaceuticals International, plc Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $30.7M +$3.54M +13.1% Jan 1, 2024 Dec 31, 2024 10-K 2025-02-25
2023 $27.1M +$2.03M +8.08% Jan 1, 2023 Dec 31, 2023 10-K 2025-02-25
2022 $25.1M -$53K -0.21% Jan 1, 2022 Dec 31, 2022 10-K 2025-02-25
2021 $25.2M +$4.3M +20.6% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-28
2020 $20.9M +$5.8M +38.4% Jan 1, 2020 Dec 31, 2020 10-K 2023-03-02
2019 $15.1M +$9.38M +165% Jan 1, 2019 Dec 31, 2019 10-K 2022-02-24
2018 $5.7M +$4.8M +536% Jan 1, 2018 Dec 31, 2018 10-K 2021-02-25
2017 $897K Jan 1, 2017 Dec 31, 2017 10-K 2019-03-12
* An asterisk sign (*) next to the value indicates that the value is likely invalid.